Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Karen Kelly of the University of California, Davis, provides her view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Phil Bonomi, from Rush University, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over the next several years. 

[powerpress]

Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]